John C Roche

THG CEO John C Roche sells 8,358 shares for $1,619,266.14 via scheduled 10b5-1 plan; holds 141,010 post-transaction

John C Roche executed 3 separate sales totaling 8,358 shares for $1,619,266.14 at an average price of $193.74 per share on 2026-05-20, reducing his holdings from 149,368 to 141,010 shares (-5.6%). The sales were conducted under a pre-arranged 10b5-1 trading plan adopted 2025-11-19, making them scheduled transactions rather than discretionary decisions. At the current price of $195.58, the stock sits near its 52-week high of $199.59 and has climbed 8.2% over the past 30 days and 11.2% over 90 days. Historical outcomes from Roche's prior trades at THG show mixed results—a sell on 2025-04-01 resulted in 30-day and 90-day declines, while three earlier sells in March 2025 yielded modest positive returns—providing limited directional context for this scheduled disposition.

Hanover Insurance CEO Roche sells 5,251 shares for $1.0M via scheduled 10b5-1 plan

John C. Roche, President and CEO of Hanover Insurance Group, executed 4 separate sales totaling 5,251 shares for $1,040,031.25 at a blended average price of $198.06, reducing his holdings from 146,261 to 141,010 shares (-3.6%). The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-19, meaning it is scheduled rather than discretionary. His prior trades at THG show mixed near-term outcomes: one April 2025 sale yielded -5.5% over 30 days, while three March 2025 sales ranged from +1.4% to +2.5% over the same period. With the stock at $193.79 current price and the insider's blended sale price at $198.06, the transaction executed near the upper end of the 52-week range ($160.70–$199.59), though no timing characterization is applicable given the scheduled nature of the plan.

THG CEO John C Roche sells 8,906 shares ($1.6M) at $175.17; retains 124.4K shares post-sale

John C Roche, President and CEO of Hanover Insurance Group, sold 8,906 shares on 2025-04-01 for $1,560,064.02, reducing his holdings from 133.3K to 124.4K shares (−6.7%). The sale occurred at $175.17, near the 52-week high of $175.14, with the stock at +0.0% from its peak and +14.9% over 90 days. His cross-ticker track record shows 3 prior open-market sells averaging +1.9% 30-day returns post-sale; his same-ticker history at THG consists of three prior sales on 2025-03-03, each with measurable positive 30-day returns (+2.5%, +1.9%, +1.4%), though the 90-day outcomes remain unmeasurable. The company trades at a P/E of 8.32 with 4.1% annual revenue growth and $1.6B quarterly revenue. No scheduled trading plan FLAGS are indicated, leaving the discretionary nature of this sale as a contextual factor for monitoring, but the modest reduction in a substantial remaining position does not indicate any wholesale portfolio shift.

THG CEO Roche sells 10,706 shares in 3 transactions for $1,842,541.06 on 2025-03-03

John C. Roche, President and CEO of Hanover Insurance Group, executed three separate sales totaling 10,706 shares for $1,842,541.06 on March 3, 2025, at prices ranging from $170.91 to $172.66. Following the sales, Roche retains 124,277 shares, representing a 7.9% reduction in his pre-transaction holdings of 134,983 shares. The transaction occurred near the stock's 52-week high of $173.00 and follows a strong 30-day price advance of 10.8%, placing the stock at elevated valuation levels. The company trades at a P/E of 8.06 with positive 90-day momentum (+3.3%) and recent quarterly revenue of $1,565,300,000.00, but this filing captures a single discrete event rather than evidence of a pattern of activity.